This study shows that, for U.S. women at risk of HIV infection, pre-exposure prophylaxis (PrEP) regimens containing maraviroc are safe and well-tolerated, compared with the standard regimen of tenofovir disoproxil fumarate/emtricitabine. The authors also found that no new infections occurred with the study regimen, compared with the standard regimen, but more research is needed to determine whether that outcome is because of the study drug and whether the enrolled population was lower risk than anticipated.
Safety and tolerability of maraviroc-containing regimens to prevent HIV infection in women: A phase 2 randomized trial
Written By
Gulick RM, Wilkin TJ, Chen YQ, Landovitz RJ, Amico KR, Young AM, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH, McGowan I, Cottle LM, Andrade A, Marcus C, Klingman KL, Chege W, Rinehart AR, Rooney JF, Andrew P, Salata RA, Siegel M, Manabe YC, Frank I, Ho K, Santana J, Stekler JD, Swaminathan S, McCauley M, Hodder S, Mayer KH
